Evidence map›Paper›PMID 36569837›Full record

ArticleFrontiers in immunology2022

Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.

Xiao Xie, Chun-Xia Dou, Ming-Rui Luo, Ke Zhang, Yang Liu, Jia-Wei Zhou, Zhi-Peng Huang, Kang-Yi Xue, Hao-Yu Liang, Ao-Rong Ouyang and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Xiao XieDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Chun-Xia DouCollege of nursing, Jinan University, Guangzhou, China.
Ming-Rui LuoState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ke ZhangThe Third Clinical college, Southern Medical University, Guangzhou, China.
Yang LiuDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Jia-Wei ZhouDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Zhi-Peng HuangDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Kang-Yi XueDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Hao-Yu LiangDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Ao-Rong OuyangDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Sheng-Xiao MaDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Jian-Kun YangDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Qi-Zhao ZhouDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Wen-Bing GuoDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Cun-Dong LiuDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Shan-Chao ZhaoDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Ming-Kun ChenDepartment of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Third Affiliated Hospital of Southern Medical University · CNJinan University · CNNanfang Hospital · CNSouthern Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Plasma cells as an important component of immune microenvironment plays a crucial role in immune escape and are closely related to immune therapy response. However, its role for prostate cancer is rarely understood. In this study, we intend to investigate the value of a new plasma cell molecular subtype for predicting the biochemical recurrence, immune escape and immunotherapy response in prostate cancer. Methods: Gene expression and clinicopathological data were collected from 481 prostate cancer patients in the Cancer Genome Atlas. Then, the immune characteristics of the patients were analyzed based on plasma cell infiltration fractions. The unsupervised clustering based machine learning algorithm was used to identify the molecular subtypes of the plasma cell. And the characteristic genes of plasma cell subtypes were screened out by three types of machine learning models to establish an artificial neural network for predicting plasma cell subtypes. Finally, the prediction artificial neural network of plasma cell infiltration subtypes was validated in an independent cohort of 449 prostate cancer patients from the Gene Expression Omnibus. Results: The plasma cell fraction in prostate cancer was significantly decreased in tumors with high T stage, high Gleason score and lymph node metastasis. In addition, low plasma cell fraction patients had a higher risk of biochemical recurrence. Based on the differential genes of plasma cells, plasma cell infiltration status of PCa patients were divided into two independent molecular subtypes(subtype 1 and subtype 2). Subtype 1 tends to be immunosuppressive plasma cells infiltrating to the PCa region, with a higher likelihood of biochemical recurrence, more active immune microenvironment, and stronger immune escape potential, leading to a poor response to immunotherapy. Subsequently, 10 characteristic genes of plasma cell subtype were screened out by three machine learning algorithms. Finally, an artificial neural network was constructed by those 10 genes to predict the plasma cell subtype of new patients. This artificial neural network was validated in an independent validation set, and the similar results were gained. Conclusions: Plasma cell infiltration subtypes could provide a potent prognostic predictor for prostate cancer and be an option for potential responders to prostate cancer immunotherapy.

Indexed as

Artificial IntelligenceProstatic NeoplasmsAlgorithmsHumansImmunotherapyMalePlasma CellsTumor Microenvironmentartificial intelligenceimmune escapeimmunotherapyplasma cellprostate cancer

Identifiers

PMID36569837
PMCPMC9772552
OpenAlexW4311853325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.